300 related articles for article (PubMed ID: 35151368)
1. Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.
Dauphinot V; Potashman M; Levitchi-Benea M; Su R; Rubino I; Krolak-Salmon P
Alzheimers Res Ther; 2022 Feb; 14(1):34. PubMed ID: 35151368
[TBL] [Abstract][Full Text] [Related]
2. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
[TBL] [Abstract][Full Text] [Related]
3. Determinants of Medical Direct Costs of Care among Patients of a Memory Center.
Dauphinot V; Garnier-Crussard A; Moutet C; Delphin-Combe F; Späth HM; Krolak-Salmon P
J Prev Alzheimers Dis; 2021; 8(3):351-361. PubMed ID: 34101794
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
[TBL] [Abstract][Full Text] [Related]
5. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
[TBL] [Abstract][Full Text] [Related]
6. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
7. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
[TBL] [Abstract][Full Text] [Related]
9. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
[TBL] [Abstract][Full Text] [Related]
10. Observation of Patient and Caregiver Burden Associated with Early Alzheimer's Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1.
Robinson RL; Rentz DM; Bruemmer V; Scott Andrews J; Zagar A; Kim Y; Schwartz RL; Ye W; Fillit HM
J Alzheimers Dis; 2019; 72(1):279-292. PubMed ID: 31561360
[TBL] [Abstract][Full Text] [Related]
11. 2022 Alzheimer's disease facts and figures.
Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden.
Sheikh F; Ismail Z; Mortby ME; Barber P; Cieslak A; Fischer K; Granger R; Hogan DB; Mackie A; Maxwell CJ; Menon B; Mueller P; Patry D; Pearson D; Quickfall J; Sajobi T; Tse E; Wang M; Smith EE;
Int Psychogeriatr; 2018 Feb; 30(2):233-244. PubMed ID: 28879833
[TBL] [Abstract][Full Text] [Related]
13. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
14. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
[TBL] [Abstract][Full Text] [Related]
15. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
[TBL] [Abstract][Full Text] [Related]
16. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression.
van de Beek M; van Steenoven I; van der Zande JJ; Barkhof F; Teunissen CE; van der Flier WM; Lemstra AW
Mov Disord; 2020 May; 35(5):859-867. PubMed ID: 32048343
[TBL] [Abstract][Full Text] [Related]
17. Disease progression and costs at the 3-year follow-up of the GERAS-US study.
Chandler JM; Rentz DM; Zagar A; Kim Y; Schwartz RL; Fillit H
Alzheimers Dement (Amst); 2023; 15(2):e12430. PubMed ID: 37091310
[TBL] [Abstract][Full Text] [Related]
18. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
